BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8655118)

  • 1. [Magnesium deficiency after kidney transplantation and cyclosporine therapy].
    Rob PM
    Fortschr Med; 1996 Apr; 114(10):125-6. PubMed ID: 8655118
    [No Abstract]   [Full Text] [Related]  

  • 2. Magnesium deficiency after renal transplantation and cyclosporine treatment despite normal serum-magnesium detected by a modified magnesium-loading-test.
    Rob PM; Bley N; Dick K; Rohwer J; Sack K
    Transplant Proc; 1995 Dec; 27(6):3442-3. PubMed ID: 8540042
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study.
    Rodrigues N; Santana A; Guerra J; Neves M; Nascimento C; Gonçalves J; da Costa AG
    Transplant Proc; 2017 May; 49(4):799-802. PubMed ID: 28457398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors after transplantation: are there associated factors?
    Jacobs U; Paar D; Buszello H; Klehr HU
    Transplant Proc; 1996 Dec; 28(6):3248. PubMed ID: 8962258
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of cyclosporine A on magnesium homeostasis: clinical observation in lung transplant recipients and experimental study in mice.
    Sabbagh F; El Tawil Z; Lecerf F; Hulin A; Maurois P; Dartevelle P; Bac P; German-Fattal M
    Transplantation; 2008 Aug; 86(3):436-44. PubMed ID: 18698248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine therapy in pancreas transplantation.
    Davidson I; Lu C; Melone D; Risser R
    Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypomagnesia and arrhythmia corrected by replacing cyclosporine with FK506 in a heart transplant recipient.
    Ko WJ; Lin FL; Wang SS; Chu SH
    J Heart Lung Transplant; 1997 Sep; 16(9):980-2. PubMed ID: 9322151
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on gingival overgrowth by cyclosporine A in renal transplants.
    Ciavarella D; Guiglia R; Campisi G; Di Cosola M; Di Liberto C; Sabatucci A; Escudero N; Bascones A; Lo Muzio L
    Med Oral Patol Oral Cir Bucal; 2007 Jan; 12(1):E19-25. PubMed ID: 17195822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C; Melchor JL
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract]   [Full Text] [Related]  

  • 10. [High prevalence of sebaceous hyperplasias in renal transplants].
    Pérez-España L; Prats I; Sanz A; Mayor M
    Nefrologia; 2003; 23(2):179-80. PubMed ID: 12778886
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine not the only agent to cause Guillain-Barré-like syndrome after solid-organ transplant.
    Hunt I
    J Heart Lung Transplant; 2006 Nov; 25(11):1387. PubMed ID: 17097509
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chronic myeloid leukemia after kidney transplantation].
    Fernández-Avilés F; Ribera JM; Batlle M; Lauzurica R
    Sangre (Barc); 1997 Feb; 42(1):85-6. PubMed ID: 9229811
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cyclosporine-induced nephropathy in patients after heart transplantation -- a significant clinical problem].
    Dziewanowski K; Kurowski M; Kopeć E; Busz-Papiez B
    Kardiol Pol; 2006 May; 64(5):522-5. PubMed ID: 16752339
    [No Abstract]   [Full Text] [Related]  

  • 15. [Uricemia-lowering activity of losartan in kidney transplantation].
    Otero Glz A; Pérez Melón C; Armada E; Gayoso P
    Nefrologia; 2002; 22(2):204-5. PubMed ID: 12085424
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical study of sandimmun neoral in cadaveric renal transplantation.
    Xue W; Chen Y; Xing J; Tian P
    Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B; Korn A
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract]   [Full Text] [Related]  

  • 18. Posttransplant diabetes mellitus in cyclosporine-treated renal allograft patients: a case-control study.
    Copstein LA; Zelmanovitz T; Gonçalves LF; Manfro RC
    Transplant Proc; 2004 May; 36(4):882-3. PubMed ID: 15194302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal alopecia areata during systemic cyclosporine A therapy.
    Cerottini JP; Panizzon RG; de Viragh PA
    Dermatology; 1999; 198(4):415-7. PubMed ID: 10490301
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.